A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases

Trial Profile

A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 19 Apr 2017 Status changed from active, no longer recruiting to recruiting.
    • 20 Sep 2016 Status changed from not yet recruiting to active, no longer recruiting.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top